Prednisolone for 12 Versus 6 Months to Treat Pulmonary Sarcoidosis

In this study, the efficacy and safety of treating pulmonary sarcoidosis with 12 months vs. 6 months of prednisolone will be compared. The hypothesis is that longer treatment DURAtion would be more effective in preventing treatment failure or early relapse in SARCoidosis (DURASARC trial). The premise of this hypothesis is that even small doses of prednisolone given over longer periods can effectively suppress disease activity in sarcoidosis without a significant increase in adverse effects.

NCT Number	NCT06654934
Lead Sponsor	Post Graduate Institute of Medical Education and Research, Chandigarh
Conditions	Sarcoidosis
Enrollment	100 participants
Start Date	2024-11
Primary Completion	2026-12 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2024-10-23